Chiesi

Chiesi Advanced Carbon Minimal Inhaler (CMI) Program with New Therapeutic Equivalence Data Presented at British Thoracic Society (BTS) Winter Meeting

Parma, Italy – 26 November 2025 – Chiesi Group, an international research-focused biopharmaceutical company and certified B Corp, today announced new data presented at the British Thoracic Society (BTS) Winter Meeting. The findings confirm that Chiesi’s beclometasone dipropionate/formoterol fumarate product formulated with hydrofluoroalkane (HFA) 152a, delivers comparable clinical efficacy and safety to the currently marketed...

Chiesi Completes Clinical Development Program for Carbon-Minimal Pressurized Metered-Dose Inhalers (pMDIs), Paving the Way for Regulatory Submissions

Successfully completed the TRECOS Phase III study, supporting the long-term safety of Chiesi’s carbon minimal pressurized metered dose inhaler (pMDI) platform Aiming to become the first pharmaceutical company to transition its broad pMDI portfolio to a next generation propellant, significantly reducing lifecycle carbon footprint Advancing the company’s plans to deliver on its Net Zero commitment...

Chiesi partners with Wirral Primary Care Collaborative to advance early detection of undiagnosed COPD

It is estimated that up to 5,000 people are living with undiagnosed COPD on the Wirral, where prevalence is more than 40% higher than the national average COPD is a leading cause of emergency hospital admissions, with an average stay of seven days Chiesi UK and Ireland and the Wirral Primary Care Collaborative have launched...

Carbon Minimal pressurised Metered Dose Inhalers (pMDIs) could save up to 619,000 tonnes of emissions each year, representing up to 7%-10% of NHS Net Zero targets

At a national level, seamless transitioning to a range of carbon minimal pMDIs could save between 415,000 and 619,000 tCO₂e annually, reducing carbon emissions to the equivalent financial value of £112 to £167 million each year in the UK alone. This represents 7%-10% of the reductions needed to achieve the NHS’s goal of reducing its...

Chiesi Group’s new Biotech Center of Excellence brings the future of medicine to Parma

Chiesi Group is making a strategic investment of €400 million to establish its new Biotech Center of Excellence in Parma The Center is designed to integrate the entire supply chain, enhancing innovation and production, while its seamless research-production integration will accelerate product development and autonomous production capacity Chiesi's strategy aligns with EU priorities on innovation,...

Chiesi Group forges alliance with Karolinska Institutet to tackle urgent health challenges

• The collaboration is underpinned by a shared commitment to advancing medical science and improving patient care through joint research, development, and innovation efforts • One of the first areas of focus under this agreement will be deepened collaborations in the field of preterm birth-associated early onset respiratory disease 14 May 2024 – Parma, Italy – Chiesi Group, a...
333 Styal Road Manchester M22 5LG United Kingdom

+44 (0)161 488 5555